Oric Pharmaceuticals Inc at Citi BioPharma Conference Transcript
Welcome, everyone. I'm Yigal Nochomovitz. I'm one of the biotech analysts at Citi. As long as I can remember, we always do a targeted oncology panel at our conference, so this is the 2023 version of that panel. So we have 3 terrific companies. From IDEAYA, Paul Stone, CFO; from ORIC, Matt Panuwat. Am I saying that correctly?
That's correct. Yes.
Okay. Good. The Chief Business Officer. And from Syndax, Mike Metzger, the CEO. So thank you all so much for taking time out of the one-on-one schedule to chat a little bit.
Maybe we can just go down the line and just do a quick 2- to 3-minute high-level overview of what the company does, what are the key assets, maybe the key studies, and then we can get into a discussion about design considerations for targeted oncology drugs. So you want to kick it off, Matt?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
